PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Serum selenium levels and the risk of progression of laryngeal cancer.

Abstract Observational studies have reported an inverse relationship between selenium status (blood or toenail) and the risk of laryngeal cancer; however, the impact of low serum selenium level on survival has not been evaluated.
PMID
Related Publications

Selenium for preventing cancer.

Toenail selenium status and risk of subtypes of head-neck cancer: The Netherlands Cohort Study.

Prospective study of toenail selenium levels and cancer among women.

A low selenium level is associated with lung and laryngeal cancers.

Serum selenium levels predict survival after breast cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 29304040
OWN - NLM
STAT- In-Data-Review
LR  - 20180105
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 1
DP  - 2018
TI  - Serum selenium levels and the risk of progression of laryngeal cancer.
PG  - e0184873
LID - 10.1371/journal.pone.0184873 [doi]
AB  - BACKGROUND: Observational studies have reported an inverse relationship between
      selenium status (blood or toenail) and the risk of laryngeal cancer; however, the
      impact of low serum selenium level on survival has not been evaluated. METHODS:
      We conducted a prospective study of 296 patients diagnosed with laryngeal cancer 
      in Szczecin, Poland. Serum selenium was measured at diagnosis and prior to
      treatment. Patients were followed from the date of diagnosis to death at five
      years. Vital status was obtained by linkage to the Polish National Death
      Registry. RESULTS: The five-year survival after diagnosis was 82.0% (95% CI: 68% 
      to 91%) for individuals in the highest quartile of serum selenium (> 66.8 mug/L) 
      and was 28.6% (95% CI 19% to 42%) for individuals in the lowest quartile (<50.0
      mug/L). In an age- and sex-adjusted analysis, the hazard ratio (HR) for death
      from all causes was 7.01 (95% CI 3.81 to 12.9) for patients in the lowest
      quartile of serum selenium, compared to those in the highest quartile. The
      corresponding multivariate HR was 3.07 (95% CI 1.59 to 5.94). CONCLUSIONS: This
      study suggests that a selenium level in excess of 70 mug/L is associated with
      improved outcome among patients undergoing treatment for laryngeal cancer.
      Further studies are needed to evaluate if selenium supplementation to achieve
      this level might improve overall prognosis.
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Clinic of Otolaryngology, Pomeranian Medical University, Szczecin, Poland.
AD  - ReadGene, Grzepnica, Poland.
FAU - Marciniak, Wojciech
AU  - Marciniak W
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Muszynska, Magdalena
AU  - Muszynska M
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Jaworowska, Ewa
AU  - Jaworowska E
AD  - Clinic of Otolaryngology, Pomeranian Medical University, Szczecin, Poland.
FAU - Sulikowski, Mieczyslaw
AU  - Sulikowski M
AD  - Clinic of Otolaryngology, Pomeranian Medical University, Szczecin, Poland.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Kaczmarek, Katarzyna
AU  - Kaczmarek K
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Sukiennicki, Grzegorz
AU  - Sukiennicki G
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Falco, Michal
AU  - Falco M
AD  - Regional Oncology Centre Szczecin, Szczecin, Poland.
FAU - Baszuk, Piotr
AU  - Baszuk P
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
FAU - Mojsiewicz, Magdalena
AU  - Mojsiewicz M
AD  - Institute of Econometric and Statistics, University of Szczecin, Szczecin,
      Poland.
FAU - Kotsopoulos, Joanne
AU  - Kotsopoulos J
AD  - Women's College Research Institute, Toronto, Canada.
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
FAU - Sun, Ping
AU  - Sun P
AD  - Women's College Research Institute, Toronto, Canada.
FAU - Narod, Steven A
AU  - Narod SA
AUID- ORCID: http://orcid.org/0000-0001-5798-0626
AD  - Women's College Research Institute, Toronto, Canada.
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
FAU - Lubinski, Jan A
AU  - Lubinski JA
AD  - ReadGene, Grzepnica, Poland.
AD  - Department of Genetics and Pathology, International Hereditary Cancer Center,
      Pomeranian Medical University, Szczecin, Poland.
LA  - eng
PT  - Journal Article
DEP - 20180105
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/04/27 00:00 [received]
PHST- 2017/09/03 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 10.1371/journal.pone.0184873 [doi]
AID - PONE-D-17-16328 [pii]
PST - epublish
SO  - PLoS One. 2018 Jan 5;13(1):e0184873. doi: 10.1371/journal.pone.0184873.
      eCollection 2018.